The company’s health services division Evernorth is unveiling new programs in a reliable growth area: assuaging payer concerns around GLP-1 coverage. Dive Brief: This article focuses on Cigna’s strategies regarding the growing demand for GLP-1 weight loss medications. Cigna’s health services division, Evernorth,…
That’s the question researchers aim to answer in a new, first-of-its-kind, clinical trial in North Texas By Bianca Castro • Published April 30, 2025 • Updated on April 30, 2025 at 10:52 pm Researchers in Dallas are investigating the potential of weight loss medications, specifically a drug called tirzepatide,…
Yaacobi Peretz, S., Kessner, R., Bar, Y. et al. Body composition metrics as a determinant of trastuzumab deruxtecan related toxicity and response. npj Breast Cancer 11, 38 (2025). This scientific article explores the connection between a patient’s body composition and their experience with…
by Jennifer H Hwang, DO; Neda Laiteerapong, MD; Elbert S. Huang, MD; David D. Kim, PhDJAMA Health Forum: 2025 Mar 7;6(3):e245586. doi: 10.1001 Published March 14, 2025 This research evaluates the cost-effectiveness of four different antiobesity medications compared to lifestyle modification alone for US…
by Michael Monostra Fact Checked by Richard Smith from Endocrine Today/Healio NewsPublished April 25, 2025 According to findings from a microsimulation model, covering obesity medications under Medicare Part D is projected to significantly increase federal spending, estimated at $47.7 billion over ten years. While…
American Heart Association by Laura Williamson, American Heart Association NewsPublished: January 14, 2025 The American Heart Association discusses healthspan, defining it as the number of years one lives free from significant chronic disease or disability, and contrasts it with life expectancy.…
Hinte LC, Castellano-Castillo D, Ghosh A, Melrose K, Gasser E, Noé F, Massier L, Dong H, Sun W, Hoffmann A, Wolfrum C, Rydén M, Mejhert N, Blüher M, von Meyenn F. Adipose tissue retains an epigenetic memory of obesity after…
What You Should Know: – PGxAI, a leader in AI-powered pharmacogenomics released a new report aimed at personalizing treatment regimens for patients taking semaglutide (commonly known by brand names Ozempic and Wegovy) and other widely used weight-management drugs. – Utilizing…
Eli Lilly has met its goal of achieving semaglutide-like efficacy with an oral GLP-1 drug. The phase 3 study linked the oral GLP-1 drug orforglipron to similar reductions in blood glucose and body weight to Novo Nordisk’s injectable blockbuster, although…
Studies suggest types of fasting can lead to moderate weight loss and other health benefits in overweight and obese people, but only some doctors use it. Medscape Medical News